GBT
DNTH icon

Grove Bank & Trust’s Dianthus Therapeutics DNTH Stock Holding History

Grove Bank & Trust’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.37K Hold
61
– – ﹤0.01% 729
2026
Q2 		$5.95K Buy
61
+2
+3% +$175 ﹤0.01% 711
2026
Q1 		$4.95K Buy
+59
New +$3.42K ﹤0.01% 709

Other funds holding DNTH

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Grove Bank & Trust's DNTH Position: Q3 2026 in Review

Grove Bank & Trust held its Dianthus Therapeutics (DNTH) position steady in Q3 2026 at 61 shares worth $5.37K. The position accounts for ﹤0.01% of the portfolio, ranked #729.

Grove Bank & Trust first reported a position in DNTH in Q1 2026 and has held it in 3 quarters since. The position peaked at $5.95K in Q2 2026. 5 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Grove Bank & Trust held 61 shares of Dianthus Therapeutics worth $5.37K as of Q3 2026.
  • Grove Bank & Trust left its Dianthus Therapeutics share count unchanged in Q3 2026.
  • Dianthus Therapeutics made up ﹤0.01% of Grove Bank & Trust's portfolio in Q3 2026, its #729 holding.
  • Grove Bank & Trust first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Grove Bank & Trust's Dianthus Therapeutics position peaked at $5.95K in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Grove Bank & Trust's 13F filing for Q3 2026, filed 8 Oct 2026.